Type 2 diabetes mellitus (T2DM) is a chronic condition associated with long-term microvascular and macrovascular complications. Evidence-based guidelines recommend the individualisation of therapies to manage hyperglycaemia in order to reduce risk of complications.
This article is based on an invited oral symposium presentation at the Diabetes UK Professional
Conference in London in March 2018. KK acknowledge the support from National Institute for
Health Research Collaboration for Leadership in Applied Health Research and Care – East Midlands
(NIHR CLAHRC – EM) and the NIHR Leicester, Biomedical Research Centre.
CitationDiabetes, Obesity and Metabolism, 2018
Author affiliation/Organisation/COLLEGE OF LIFE SCIENCES/School of Medicine/Diabetes Research Centre
VersionAM (Accepted Manuscript)
NotesThe file associated with this record is under embargo until 12 months after publication, in accordance with the publisher's self-archiving policy. The full text may be available through the publisher links provided above.